Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer

Medical Oncology

Volumn 27, Issue 3, 2010, Pages 992-997

  Choi, In Sil ^b   Lee, Keun Wook ^a   Kim, Ki Hwan ^a   Kim, Yu Jung ^a   Kim, Jee Hyun ^a   Lee, Jong Seok ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Chemotherapy; Cisplatin; Gastric cancer; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LIVER TOXICITY; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FATIGUE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; OXONIC ACID; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; TEGAFUR; TREATMENT OUTCOME;

EID: 77956920951     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9321-x     Document Type: Article

References (20)

1. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 74 108 10.3322/canjclin.55.2.74 15761078
2. S Pyrhonen T Kuitunen P Nyandoto M Kouri 1995 Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 587 591 1:STN:280:DyaK2M7os1ertg%3D%3D 7533517
3. AM Murad, et al. 1993 Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer Cancer 72 37 41 10.1002/1097- 0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P 1:STN:280: DyaK3s3osVGqtQ%3D%3D 8508427
4. B Glimelius, et al. 1997 Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer Ann Oncol 8 163 168 10.1023/A:1008243606668 1:STN:280:DyaK2s3kslGqug%3D%3D 9093725 (Pubitemid 27112884)
5. U Vanhoefer, et al. 2000 Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group J Clin Oncol 18 2648 2657 1:CAS:528:DC%2BD3cXls12iurk%3D 10894863
6. IS Choi, et al. 2007 Oxaliplatin, 5-FU, folinic acid as first-line palliative chemotherapy in elderly patients with metastatic or recurrent gastric cancer Cancer Res Treat 39 99 103 10.4143/crt.2007.39.3.99 19746224
7. D Cunningham, et al. 2008 Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 36 46 10.1056/NEJMoa073149 1:CAS:528:DC%2BD1cXisFSktg%3D%3D 18172173
8. YK Kang, et al. 2009 Capecitabine/cisplatin versus 5-fluorouracil/ cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial Ann Oncol 20 666 673 10.1093/annonc/mdn717 19153121
9. KW Lee, et al. 2005 Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer Jpn J Clin Oncol 35 720 726 10.1093/jjco/hyi198 16332718 (Pubitemid 43102078)
10. E Van Cutsem, et al. 2006 Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group J Clin Oncol 24 4991 4997 10.1200/JCO.2006.06.8429 17075117 (Pubitemid 46631401)
11. MD Seo, et al. 2008 Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer Jpn J Clin Oncol 38 589 595 10.1093/jjco/hyn078 18772169
12. T Shirasaka, et al. 1996 Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 548 557 10.1097/00001813-199607000-00010 1:CAS:528: DyaK28Xltleru78%3D 8862723
13. Y Sakata, et al. 1998 Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715 1720 10.1016/S0959- 8049(98)00211-1 1:CAS:528:DyaK1cXntlShurw%3D 9893658 (Pubitemid 28474225)
14. W Koizumi M Kurihara S Nakano K Hasegawa 2000 Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 cooperative gastric cancer study group Oncology 58 191 197 10.1159/000012099 1:CAS:528:DC%2BD3cXjvVeitr4%3D 10765119
15. W Koizumi, et al. 2003 Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer Br J Cancer 89 2207 2212 10.1038/sj.bjc.6601413 1:CAS:528:DC%2BD3sXpvVShtbc%3D 14676796 (Pubitemid 38168001)
16. JA Ajani, et al. 2005 Phase I Pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma J Clin Oncol 23 6957 6965 10.1200/JCO.2005.01.917 1:CAS:528:DC%2BD2MXhtFCrsbjM 16145066
17. JA Ajani, et al. 2006 Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma J Clin Oncol 24 663 667 10.1200/JCO.2005.04.2994 1:CAS:528:DC%2BD28XhvFKhtLs%3D 16446338 (Pubitemid 46630431)
18. JL Lee, et al. 2008 Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer Cancer Chemother Pharmacol 61 837 845 10.1007/s00280-007-0541-5 1:CAS:528: DC%2BD1cXitleqsrs%3D 17579864 (Pubitemid 351305943)
19. H Iwase, et al. 2005 A phase II multicentric trial of S-1 combined with 24 h-infusion of cisplatin in patients with advanced gastric cancer Anticancer Res 25 1297 1301 1:CAS:528:DC%2BD2MXkt1Wnurk%3D 15865081
20. W Koizumi, et al. 2008 S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 215 10.1016/S1470-2045(08)70035-4 1:CAS:528:DC%2BD1cXivVaqtb4%3D 18282805